Literature DB >> 9462188

Changes in oxygenation and pulmonary haemodynamics in preterm infants treated with inhaled nitric oxide.

N V Subhedar1, N J Shaw.   

Abstract

AIM: To investigate changes in various cardiorespiratory variables with inhaled nitric oxide (NO), as part of a randomised controlled trial.
METHODS: Infants were treated with inhaled NO for 72 hours. Changes in oxygenation were assessed using the oxygenation index (OI). Serial changes in pulmonary artery pressure (PAP) were assessed using the Doppler derived acceleration time to right ventricular ejection time ratio (AT:RVET). Doppler measurements of right ventricular output, pulmonary blood flow, and systolic PAP was performed in a subset of infants.
RESULTS: Twenty infants received inhaled NO and 22 acted as controls. Infants were treated at a median dose of 5 (range 5 to 20) ppm. There was a fall in median OI by 17% in treated infants within 30 minutes of treatment. The fall in OI in treated infants was significantly different from the response in controls until 96 hours. Infants treated with inhaled NO showed a rapid response with a median rise in AT:RVET of 0.04 (range -0.06 to 0.12) within 30 minutes. The change in AT:RVET was significantly different from controls until 4 hours. Median systolic PAP also fell in treated infants by 6.1 (range -14.4 to -4.4) mm Hg within 1 hour. Changes in OI were significantly associated with changes in PBF (r = 0.44), but not with changes in AT:RVET.
CONCLUSION: Treatment with inhaled NO rapidly improves oxygenation and lowers PAP in preterm infants. However, these effects are transient and treatment does not influence long term outcome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9462188      PMCID: PMC1720723          DOI: 10.1136/fn.77.3.f191

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  35 in total

1.  Safety guidelines for use of nitric oxide.

Authors:  L Foubert; B Fleming; R Latimer; M Jonas; A Oduro; C Borland; T Higenbottam
Journal:  Lancet       Date:  1992-06-27       Impact factor: 79.321

2.  Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn.

Authors:  J P Kinsella; S R Neish; E Shaffer; S H Abman
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

3.  Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome.

Authors:  H Gerlach; R Rossaint; D Pappert; K J Falke
Journal:  Eur J Clin Invest       Date:  1993-08       Impact factor: 4.686

4.  Inhaled nitric oxide in congenital heart disease.

Authors:  J D Roberts; P Lang; L M Bigatello; G J Vlahakes; W M Zapol
Journal:  Circulation       Date:  1993-02       Impact factor: 29.690

5.  Shunts in patients with respiratory distress syndrome.

Authors:  N Evans
Journal:  Pediatrics       Date:  1993-11       Impact factor: 7.124

6.  Bleeding time prolongation and NO inhalation.

Authors:  M Högman; C Frostell; H Arnberg; G Hedenstierna
Journal:  Lancet       Date:  1993-06-26       Impact factor: 79.321

7.  Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response.

Authors:  N N Finer; P C Etches; B Kamstra; A J Tierney; A Peliowski; C A Ryan
Journal:  J Pediatr       Date:  1994-02       Impact factor: 4.406

8.  Inhaled nitric oxide for the adult respiratory distress syndrome.

Authors:  R Rossaint; K J Falke; F López; K Slama; U Pison; W M Zapol
Journal:  N Engl J Med       Date:  1993-02-11       Impact factor: 91.245

9.  Hemodynamic effects of exogenous nitric oxide in ovine transitional pulmonary circulation.

Authors:  J P Kinsella; J A McQueston; A A Rosenberg; S H Abman
Journal:  Am J Physiol       Date:  1992-09

10.  Doppler assessment of pulmonary artery pressure and extrapulmonary shunting in the acute phase of hyaline membrane disease.

Authors:  N J Evans; L N Archer
Journal:  Arch Dis Child       Date:  1991-01       Impact factor: 3.791

View more
  7 in total

Review 1.  Current perspectives on the drug treatment of neonatal respiratory distress syndrome.

Authors:  D G Sweet; H L Halliday
Journal:  Paediatr Drugs       Date:  1999 Jan-Mar       Impact factor: 3.022

Review 2.  Inhaled nitric oxide treatment for preterm infants with hypoxic respiratory failure.

Authors:  R L Smyth
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 3.  A risk-benefit assessment of drugs used for neonatal chronic lung disease.

Authors:  D G Sweet; H L Halliday
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

4.  Effects of early inhaled nitric oxide therapy and vitamin A supplementation on the risk for bronchopulmonary dysplasia in premature newborns with respiratory failure.

Authors:  Monika M Gadhia; Gary R Cutter; Steven H Abman; John P Kinsella
Journal:  J Pediatr       Date:  2013-12-31       Impact factor: 4.406

5.  Association of Early Inhaled Nitric Oxide With the Survival of Preterm Neonates With Pulmonary Hypoplasia.

Authors:  Kevin R Ellsworth; Marc A Ellsworth; Amy L Weaver; Kristin C Mara; Reese H Clark; William A Carey
Journal:  JAMA Pediatr       Date:  2018-07-02       Impact factor: 16.193

Review 6.  Inhaled nitric oxide use in neonates: Balancing what is evidence-based and what is physiologically sound.

Authors:  Laurie G Sherlock; Clyde J Wright; John P Kinsella; Cassidy Delaney
Journal:  Nitric Oxide       Date:  2019-12-19       Impact factor: 4.427

Review 7.  Inhaled nitric oxide for respiratory failure in preterm infants.

Authors:  Keith J Barrington; Neil Finer; Thomas Pennaforte
Journal:  Cochrane Database Syst Rev       Date:  2017-01-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.